These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19909896)

  • 1. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The newer fluoroquinolones.
    Bolon MK
    Med Clin North Am; 2011 Jul; 95(4):793-817, viii. PubMed ID: 21679792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will fluoroquinolones ever be recommended for common infections in children?
    Schaad UB
    Pediatr Infect Dis J; 2007 Oct; 26(10):865-7. PubMed ID: 17901790
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone antibiotics in infants and children.
    Schaad UB
    Infect Dis Clin North Am; 2005 Sep; 19(3):617-28. PubMed ID: 16102652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects.
    Sharma PC; Jain A; Jain S
    Acta Pol Pharm; 2009; 66(6):587-604. PubMed ID: 20050522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.
    Lode HM
    Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
    Fuller JD; Low DE
    Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of systemic and topical fluoroquinolones.
    Bradley JS; Jackson MA; ;
    Pediatrics; 2011 Oct; 128(4):e1034-45. PubMed ID: 21949152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage.
    Pletz MW; van der Linden M; von Baum H; Duesberg CB; Klugman KP; Welte T;
    Int J Med Microbiol; 2011 Jan; 301(1):53-7. PubMed ID: 20692869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones: then and now.
    Pallo-Zimmerman LM; Byron JK; Graves TK
    Compend Contin Educ Vet; 2010 Jul; 32(7):E1-9; quiz E9. PubMed ID: 20957609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals.
    Martinez M; McDermott P; Walker R
    Vet J; 2006 Jul; 172(1):10-28. PubMed ID: 16154368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.